OSCR · Oscar Health, Inc. — research history

Oscar Health reported exceptional Q1 2026 results (net income of ~$679M on $4.65B revenue vs. $275M / $3.05B in Q1 2025) with effectuated membership surging from 2.04M to 3.2M members. The company reaffirmed FY2026 guidance at the June 8, 2026 Goldman Sachs healthcare conference fireside chat. However, Mario Schlosser, co-founder and former CTO/President, transitioned to Co-Founder & Advisor effective June 1 — forfeiting bonus eligibility and future equity grants but continuing to vest prior awards. No open-market insider purchases were detected in Form 4s reviewed; all recent filings appear to be equity award-related rather than discretionary buys. The stock trades near its 52-week high with a market cap of ~$6B+. The primary regulatory overhang is the eAPTC (enhanced Advanced Premium Tax Credits) program — currently extended through at least 2026 under existing law, but Congressional renewal beyond that window represents a material multi-year risk factor for Oscar's core ACA individual-market business. No smart-money cluster signal, no mispriced thesis, and limited near-term asymmetric upside given valuation and position in the range.

The stock trades near all-time highs with a consensus target below the current price, leaving zero mispricing or margin of safety. Anti-signals for dilution and accounting are material and cannot be dismissed, and heavy CFO selling combined with a fully priced-in Q1 beat eliminates any viable thesis or income edge.

OSCR reported exceptional Q1 2026 results — net income of $679M vs. consensus estimate of ~$110M EPS beat — with revenue up 52% YoY and membership growing to ~3.2M effectuated members from 2.0M at FYE25. The CFO sold ~210,000 shares totaling ~$4.7-5.1M via pre-scheduled Rule 10b5-1 plans (adopted Feb 12, 2026) on May 14 and May 18 while the stock was hitting 52-week highs near $23–25. CMS also formally reduced ACA user fees — a positive regulatory catalyst. The stock is up ~58% YTD from its March 2026 low of ~$10.85 and sits at/near all-time highs (~7% below 52w high). Forward P/E of 15.7x looks reasonable but not cheap vs. sector, and the analyst consensus target sits at $21.20 — marginally below current price. The Q1 beat was largely priced in by early May; there is no clear residual mispricing after the +58% YTD run.

The stock has already re-rated 150% from March lows to a 52-week high, trading in-line with sector peers on forward multiples with no identifiable mispricing edge. Heavy insider selling and elevated RSI further negate both long and income setups at current levels.

Oscar Health reported a stunning Q1 2026 beat ($2.07 vs $1.10 estimate), more than doubling net income to $679M with revenue of $4.65B (+53% YoY). Membership grew to ~3.2M effectuated members (from 2.0M at year-end 2025) and medical loss ratio improved sharply. The stock hit a 5-year high near $25 in May 2026 following the print. However, both Form 4 filings triggering this investigation are SELL transactions under pre-arranged Rule 10b5-1 plans adopted February 12 — CFO Blackley liquidated ~210K shares at $23-25, and two directors received deferred stock units as compensation (not open-market buys). There is no genuine insider purchase cluster. The company appears operationally transformed with strong membership growth and margin expansion, but at current levels near the top of its historical range there is no clear mispricing edge — forward P/E ~17x sits in-line with health insurance peers rather than discounted to them. The stock is above both 50- and 200-DMAs, RSI at 69 is elevated, and implied volatility (70% ATM on June expiry) is high enough for income strategies but not indicative of an asymmetric long setup.